Emergent BioSolutions Inc (EBS)
6.81
-0.17
(-2.44%)
USD |
NYSE |
Jun 28, 16:00
6.85
+0.04
(+0.59%)
After-Hours: 20:00
Emergent BioSolutions Research and Development Expense (Annual): 111.40M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 111.40M |
| December 31, 2022 | 188.30M |
| December 31, 2021 | 235.20M |
| December 31, 2020 | 237.90M |
| December 31, 2019 | 226.20M |
| December 31, 2018 | 142.80M |
| December 31, 2017 | 97.40M |
| December 31, 2016 | 106.90M |
| December 31, 2015 | 119.19M |
| December 31, 2014 | 104.72M |
| December 31, 2013 | 119.93M |
| Date | Value |
|---|---|
| December 31, 2012 | 120.23M |
| December 31, 2011 | 124.83M |
| December 31, 2010 | 89.30M |
| December 31, 2009 | 74.59M |
| December 31, 2008 | 59.47M |
| December 31, 2007 | 53.96M |
| December 31, 2006 | 45.50M |
| December 31, 2005 | 18.38M |
| December 31, 2004 | 10.12M |
| December 31, 2003 | |
| December 31, 2002 | 2.808M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
111.40M
Minimum
2023
237.90M
Maximum
2020
199.80M
Average
226.20M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Macrogenics Inc | 166.58M |
| Verrica Pharmaceuticals Inc | 20.30M |
| Recursion Pharmaceuticals Inc | 241.23M |
| Omega Therapeutics Inc | 77.17M |
| Context Therapeutics Inc | 17.78M |